Kevin Church - Feb 14, 2024 Form 4 Insider Report for Athira Pharma, Inc. (ATHA)

Role
CHIEF SCIENTIFIC OFFICER
Signature
/s/ Mark Worthington, Attorney-in-Fact for Kevin Church
Stock symbol
ATHA
Transactions as of
Feb 14, 2024
Transactions value $
$0
Form type
4
Date filed
2/16/2024, 04:54 PM
Previous filing
Jan 8, 2024
Next filing
Sep 5, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ATHA Stock Option (Right to Buy) Award $0 +220K $0.00 220K Feb 14, 2024 Common Stock 220K $3.26 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares subject to the option shall be scheduled to vest monthly over a term of 48 months on the monthly anniversaries of the grant date, subject to the optionee continuing to be a Service Provider (as defined in the Issuer's 2020 Equity Incentive Plan) through the applicable vesting dates.